Bracket Announces New Study for Assessment of Brain Insulin Resistance in Alzheimer's Disease
Researchers to Utilize Proprietary CDR System™ from the Bracket eCOA™ Product Line
WAYNE, Pa., Oct. 19, 2016 /PRNewswire/ -- Bracket, a leading clinical trial technology and specialty services provider with expertise in Alzheimer's Disease, announced today a new study partnership with researchers at Massachusetts General Hospital (MGH) on the 'Assessment of Brain Insulin Resistance in Alzheimer's Disease Using an Insulin Clamp'. The researchers will utilize its proprietary CDR System™ in the study, which is both a product of the Bracket eCOA™ product line and the industry standard for automated assessment of cognitive function in clinical trials.
The study will determine the effects of hyperinsulinemia on brain physiology, brain electrophysiological responses, and neurocognitive performance among subjects with and without Alzheimer's Disease. Brain insulin resistance is emerging as a major mechanism of interest in Alzheimer's Disease. While data from autopsy studies and animal research have shown that neurons are resistant to insulin in Alzheimer's Disease, it has been difficult to directly demonstrate this in humans.
"Using advanced neuroimaging, electrophysiology, and cognitive testing methods from Bracket's CDR System, we are comparing the effects of experimentally-induced high insulin levels on the brains of individuals with Alzheimer's Disease and healthy older adults," said Aaron Koenig, Assistant in Psychiatry, at Massachusetts General Hospital. "This is an important study that could clearly establish the presence of an abnormal brain insulin response in Alzheimer's Disease, and may provide useful tools for current and future treatment research in this very common disorder."
Early-to-market with a flexible platform for eCOA and with specialties in Alzheimer's Disease trial technology and services, Bracket's CDR System provides clients with the most sensitive set of tests ever developed to assess improvements and impairments in cognitive function. The system assesses the major domains of cognitive function that are vulnerable to aging, fatigue, disease, pathology, trauma, diet and pharmaceuticals. To date, the system has been used in more than 1,200 trials across 50 indications.
"Establishing new targets for therapeutic interventions in Alzheimer's Disease is essential. This study is an exciting opportunity to explore a new pathway, and we feel that the CDR System is particularly well-suited to help identify any potential signals," said Professor Keith Wesnes, developer of the CDR System and a consultant to Bracket.
To learn more about Bracket's CDR System for Alzheimer's Disease, visit www.bracketglobal.com.
About Bracket
Bracket, with seven offices and more than 500 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com.
Contact
Kristen Everett
Sagefrog Marketing Group on behalf of Bracket
[email protected]
267-357-7018
Logo - http://photos.prnewswire.com/prnh/20141110/157718LOGO
SOURCE Bracket
Share this article